Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Acumen Pharmaceuticals, Inc. Director's Dealing 2021

Jul 2, 2021

34208_dirs_2021-07-02_7be0bb1b-aa25-42c2-abd2-c26d08763399.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-06-30

Reporting Person: Sevigny Jeffrey (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-30 Stock Option (Right to Buy) $16.00 A 34000 Acquired 2031-06-30 Common Stock (34000) Direct

Footnotes

F1: The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control.